Galecto Inc (NASDAQ: GLTO), a biopharmaceutical company focused on blood cancer therapeutics, successfully closed its underwritten public offering of 16,644,737 shares at $19.00 per share, generating gross proceeds of $316.3 million. The offering included the full exercise of underwriters' option to purchase additional shares.

Galecto, Inc. (NASDAQ: GLTO) announced the pricing of an underwritten public offering of 14.47 million shares at $19.00 per share, expected to raise approximately $275 million in gross proceeds. The offering is expected to close on February 12, 2026. Jefferies, Leerink Partners, Evercore ISI, and Guggenheim Securities are serving as joint book-ru...

Galecto's Board of Directors approved granting 312,535 non-qualified stock options to a new employee at an exercise price of $32.00, with a vesting schedule starting from the first anniversary of the grant date.

Galecto Inc. acquired Damora Therapeutics, expanding its blood cancer pipeline and securing $284.9 million in funding through a private placement, with plans to advance multiple therapeutic programs targeting myeloproliferative neoplasms and acute myeloid leukemia.

Galecto acquired Damora Therapeutics, a biotechnology company developing therapies for myeloproliferative neoplasms, in a transaction accompanied by a $285 million private investment that positions the company to advance potentially breakthrough treatments for blood cancers.